Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Operating activities:
Net income (loss)	$ 48,325	$ (18,733)
Depreciation	111	86
Accretion of debt discount and loan costs	1,040	99
Amortization of intangible assets	1,369	243
Stock-based compensation expense	3,070	4,111
Deferred income taxes	(15,972)
Bargain purchase gain	(27,336)
Changes in assets and liabilities:
Accounts receivable	(3,531)	356
Inventories, net of effect of acquisition	633	(2,263)
Prepaid expenses and other assets	194	118
Accounts payable and accrued expenses, net of effect of acquisition	4,811	(438)
Deferred revenue	(21,716)	(235)
Net cash flows from operating activities	(9,002)	(16,656)
Investing activities:
Purchase of equipment		(236)
Net cash flows from investing activities		(236)
Financing activities:
Proceeds from notes payable	45,000
Payment of notes payable	(30,000)
Payment of deferred financing fees	(2,798)
Equity financing costs		40
Proceeds from exercise of stock options		225
Proceeds from issuance of common stock		2,460
Net cash flows from financing activities	12,202	2,725
Net change in cash and cash equivalents	3,200	(14,167)
Cash and cash equivalents at beginning of year	32,019	83,560
Cash and cash equivalents at end of period	35,219	69,393
Cash paid for interest	946	$ 679
Non-cash Financing and Investing Activities:
Fair value of bargain purchase price of BELBUCA acquisition	27,300
Fair value of warrants, in connection with CRG term loan	$ 4,500